◀ Back to PARP2
PARP2 — VEGFA
Text-mined interactions from Literome
Obrosova et al., Int J Mol Med 2004
(Diabetes Mellitus, Experimental...) :
In conclusion,
PARP is
involved in diabetes- and hypoxia induced
VEGF production at post-transcriptional level, downstream from the sorbitol pathway activation and oxidative stress
Zheng et al., Diabetes 2010
(Diabetes Mellitus, Experimental...) :
Simvastatin significantly upregulated PGC-1alpha ( P < 0.01 ), subsequently decreased Deltapsim ( P < 0.05 ) and ROS generation ( P < 0.01 ),
inhibited PARP activation ( P < 0.01 ), and further reduced
VEGF expression ( P < 0.01 ) and p38 MAPK activity ( P < 0.01 )
Sledge et al., Surg Oncol Clin N Am 2010
(Breast Neoplasms) :
Novel targeted therapies under development, many currently being examined in the adjuvant setting, are also explored, including
anti-vascular endothelial growth factor therapy, poly ( ADP ribose ) polymerase (
PARP )
inhibition for triple negative breast cancers, and agents targeting site-specific metastasis to the bone ( receptor activator of NF-kB [ RANK ] ligand inhibition )